Introduction to Pd L1 Antibodies
Sentence Examples
Discover more insights into Pd L1 Antibodies
Keywords frequently search together with Pd L1 Antibodies
Narrow sentence examples with built-in keyword filters
Pd L1 Antibodies sentence examples within cell lung cancer
Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non–small cell lung cancer (NSCLC).
Full Text
The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included.
Full Text
We examined the infiltration of immune cells and expression of PD-L1 in immune cells using fluorescent multiplex immunohistochemistry (mIHC) stained with CD8/CD68/CD163/PD-L1 antibodies.
Full Text
The study evaluates whether PD-L1 mRNA copies per ml in plasma-derived exosomes may predict response to anti-PD-L1 antibodies early in the course of therapy.
Full Text
e21173 Background: Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies, are becoming standard of care for lung cancer treatment.
Full Text
Based on these findings, therapy with PD-L1 antibodies, PD-1 antibodies, gemcitabine, or dasatinib was suggested.
Full Text
Background: Multiple anti-PD-1/PD-L1 antibodies have been approved, and in some diseases, there is a choice of more than one.
Full Text
Our study uncovers a novel mechanism in control of CMTM6 and therefore PD-L1 expression, and suggests the potential of combining HuR inhibitor with PD-1/PD-L1 antibodies for cancer immunotherapy.
Full Text
Immunerelated adverse events (irAEs) under treatment with antiPD-1/anti-PD-L1 antibodies are frequent (relative frequency 70%).
Full Text
Anti-PD-L1 antibodies can inhibit these intrinsic functions of PD-L1.
Full Text
The independent binding site of anti-PD-L1-B11 relative to therapeutic anti-PD-L1 antibodies may be advantageous for anti-PD-L1 therapy monitoring.
Full Text
This study evaluates two novel TGFβ inhibitors as mono or combinatorial therapy with anti–PD-L1 antibodies (α-PD-L1 Ab) in a murine OSCC model.
Full Text
Avelumab is cleared faster and has a shorter half-life than other anti–PD-L1 antibodies, such as atezolizumab and durvalumab, but the mechanisms underlying these differences are unknown.
Full Text
While anti-PD1/PD-L1 antibodies have activity in pts with HPV-associated cancers, the majority do not derive benefit from these agents as monotherapy.
Full Text
Notably, combining BD0801 with either anti-PD-1 or anti-PD-L1 antibodies showed synergistic antitumor efficacy in both lung and colorectal cancer mouse models.
Full Text
Anti-PD-1 and anti-PD-L1 antibodies increase KCa3.
Full Text
Here, using a large-scale retrospective analysis of three independent cohorts of patients with cancer who were treated with anti-PD-1 or anti-PD-L1 antibodies, we show that the presence of mature TLSs was associated with improved objective response rates, progression-free survival and overall survival, independent of PD-L1 expression status and CD8+ T cell density.
Full Text
Methods: A series of αPD-L1 antibodies were radiolabeled with zirconium-89 for PET imaging to screen the most suitable antibodies for RIT.
Full Text
Although manipulation of immune regulation by blocking immune checkpoints has led to substantial benefit in many cancers, experience with single-agent CTLA-4 and PD-1 or PD-L1 antibodies has shown limited effect for the majority of patients with prostate cancer, especially when administered as monotherapy.
Full Text
Photodynamic therapy (PDT) is commonly used as an " in situ vaccine" to enhance the response rate of PD-1/PD-L1 antibodies.
Full Text
Conclusions:Anti-pituitary and anti-hypothalamus antibodies seem to play a pivotal role in hypothalamic–pituitary autoimmunity and secondary endocrine-related alterations evoked by anti-PD-1 and PD-L1 antibodies.
Full Text
TKIs-based combinatorial therapies with immune checkpoint inhibitors such as PD-1/PD-L1 antibodies afford a promising strategy to further clinical application.
Full Text
At this point, immunotherapy, including anti-PD-1 and anti-PD-L1 antibodies, renders an innovative and more effective way to take advantage of our own immune response to kill cancer cells.
Full Text
Immune checkpoint inhibitors such as anti PD-1/PD-L1 antibodies have proven successful in advanced mismatch repair deficient endometrial cancers with use now being investigated beyond this population.
Full Text
Our paper shows that, despite the important amount of work performed in this field, there is not yet a validated and efficient solution for the prediction of the activity and/or the toxicity of anti-PD-1 and anti-PD-L1 antibodies.
Full Text
Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non–small cell lung cancer (NSCLC).
Full Text
Immune-related toxicities are closely associated with the known mechanisms of action of both PD-1 and PD-L1 antibodies, after restarting the anticancer immune system.
Full Text
Inspired by the PD-1/PD-L1 antibodies, which have achieved great success in clinical, other immune checkpoint proteins have drawn increasing attention in cancer research.
Full Text
Based on this, we investigated how CHI3L1 acts on the proliferation and apoptosis of DLBCL and whether there is a synergy of CHI3L1 in combination with anti-PD-L1 antibodies in vivo.
Full Text
Checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, have been shown to be extraordinarily effective, but their durable response rate remains low, especially in colorectal cancer (CRC).
Full Text
Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC).
Full Text
Blockade of the TGF-β pathway which plays a key role in immune suppression may enhance the tumor response to anti-PD-1/PD-L1 antibodies.
Full Text
We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) analysis.
Full Text
The PD-L1 expression level in tumor tissue sections is currently detected via immunohistochemistry (IHC) using anti-PD-L1 antibodies from various resources, which has the disadvantage of inconsistent results.
Full Text
The possible link between the CD38 and PD-1/PD-L1 pathways is also reported, highlighting the rationale for the potential use of a combined therapeutic approach with CD38 blocking agents and anti-PD-1/PD-L1 antibodies in order to improve their anti-tumoral effect in MM patients.
Full Text
We conjugated lipid-coated SPIO nanoparticles with PD-L1 antibodies to identify PD-L1 expression in glioblastoma or temozolomide-resistant glioblastoma by using MRI.
Full Text
Methods: We reviewed patients with extensive-stage SCLC who have failed in first-line or beyond chemotherapy and received PD-1/PD-L1 antibodies with chemotherapy in a single institute.
Full Text
Immunohistochemistry was performed to the all cases by using anti-CD163, anti-NFATc1 and anti-PD-L1 antibodies.
Full Text
This article will review the scientific rationale of targeting the PD1/PD-L1 axis in NPC, and summarizes the latest trials involving these agents and predictive biomarkers of response to PD-1/PD-L1 antibodies in NPC.
Full Text
Immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies have led to a paradigm shift in advanced, metastatic ESCC treatment; however, the effect of incorporating checkpoint inhibitors in the definitive management of ESCC is unclear.
Full Text
Although immunotherapy has achieved great clinical success in clinical outcomes, especially the anti-PD-1 or anti-PD-L1 antibodies, not all patients respond to anti-PD-1 immunotherapy.
Full Text
However, 50 to 60% do not respond to single-agent anti-PD‑1/PD-L1 antibodies, and approximately 50% of responders relapse within 6 to12 months.
Full Text
Significantly, PD-L1 antibodies that confine the tumor-intrinsic PD-L1/Snail pathway restricted TNBC progression in immunodeficient mice.
Full Text
Patients were excluded if they had received prior PARP inhibitors or anti-PD-1/PD-L1 antibodies.
Full Text
This demonstrates that anti-PD-L1 antibodies could be used as theranostics in molecular imaging but also in targeted alpha-particle therapy to treat the tumor and its stroma.
Full Text
We also highlight existing research on the development of different combination therapies with anti-PD-1/PD-L1 antibodies.
Full Text
The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included.
Full Text
TPS9128 Background: Monotherapy with programmed death 1 (PD-1)/PD-L1 antibodies has improved clinical outcomes for patients (pts) with non-oncogenic driven NSCLC but clinical responses are limited by primary and secondary resistance, and improvements in durability of response are required.
Full Text
Clinical and radiologic data from 125 NSCLC patients treated with anti-PD-1 or PD-L1 antibodies between 2011 and 2018 at two tertiary academic institutions were retrospectively reviewed.
Full Text
Background: Trial-level meta-analysis to investigate differences in immune-related adverse event (irAE) profiles between anti-PD-1/PD-L1 antibodies.
Full Text
In the immunotherapy of sepsis, whether in animal experiments or in vitro clinical trials, anti-PD-1/PD-L1 antibodies have shown good promise.
Full Text
Acceptors of each grade-related branch received specific anti-PD-L1 antibodies.
Full Text
Preclinical data suggest that concurrent treatment of anti-CD38 and anti-PD-1/PD-L1 antibodies substantially reduce primary tumor growth via suppressing acquired resistance to immune checkpoint blockade, and thus enhancing anti-PD-1/PD-L1 efficacy.
Full Text
PD-L1, quantified using immunohistochemistry assays, is currently the most widely validated, used and accepted biomarker to guide the selection of patients to receive anti-PD-1 or anti-PD-L1 antibodies.
Full Text
The various assays related to immune checkpoint inhibitors are also discussed, consisting of immunohistochemistry with anti-PD-L1 antibodies SP142 and 22C3, and detection of microsatellite instability, mismatch repair deficiency, and tumor mutational burden.
Full Text
METHODS AND RESULTS
We analyzed forty-three whole sections of HNSCC with two different anti-PD-L1 antibodies, 22C3 pharma Dx and SP263 assay.
Full Text
Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies, are approved in several human cancers, however, ICIs are not approved in thymic carcinoma.
Full Text
To establish the impact of SiglecFhigh neu on anti-tumoral immune responses we treated cohort of animals with anti-PD-L1 antibodies to evaluate tumor growth in control conditions and under therapy.
Full Text
However, whether PD-L1 antibodies against different epitopes of PD-L1 antigens responding to deglycosylation has not been characterized.
Full Text
For patients with advanced-stage NSCLC lacking a targetable driver alteration, anti-PD-1/PD-L1 antibodies are now the cornerstone of first-line therapy.
Full Text
Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies.
Full Text
Recent advances have shown beneficial responses to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies.
Full Text
This study will also explore the potential utility of PF-07265807 in combination with anti-PD-1/PD-L1 antibodies.
Full Text
Lately, PD-1/PD-L1 antibodies have illustrated unprecedented curative effects in the field of Hodgkin's lymphoma and some solid tumors.
Full Text
Immune-related pneumonitis is an important toxicity associated with checkpoint inhibitor therapy with anti-PD-1 or anti-PD-L1 antibodies, often necessitating discontinuation of treatment.
Full Text
Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”.
Full Text
Although anti-PD-1/PD-L1 antibodies have achieved significant survival benefits in several kinds of solid tumors, the phase III clinical trial Checkmate 143 demonstrated that nivolumab, which targets PD-1, did not achieve survival benefits compared with bevacizumab in recurrent glioblastoma (rGB) patients.
Full Text
We report here a case series of BP associated with combined treatment using anti-PD-1/ PD-L1 antibodies and novel agents targeting transforming growth factor (TGF)-β, an immunosuppressive cytokine upregulated in the cancer microenvironment (4, 5).
Full Text
Here, we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with PARP inhibitors (PARPi) and immune checkpoint blockade with anti–PD-L1 antibodies.
Full Text
Anti-PD1/PD-L1 antibodies have only limited clinical activity.
Full Text
In vitro, we show that PRS-344/S095012 activity is superior to PD-L1 antibodies, and to the combination of clinically relevant 4-1BB and PD-L1 benchmark antibodies.
Full Text
However, given that large numbers of patients with HNSCC do not respond to PD-1/PD-L1 antibodies, combination strategies for elevating the response rate need to be further investigated.
Full Text
This systematic review included studies that investigated the analytical concordance of immunohistochemistry assays utilizing two or more PD-L1 antibodies from FDA-approved diagnostics for evaluation of PD-L1 expression on tumor or immune cells across a range of tumor types and algorithms.
Full Text
Synergy between R and anti–PD-1/PD-L1 antibodies has been demonstrated in pre-clinical models compared to that of either treatment alone.
Full Text
A total of 163 GBMs IDH wildtype were immunostained with anti-Galectin-9 and PD-L1 antibodies.
Full Text